Compare Stocks: TRLV, CRNX, BLTE, and LQDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$159.56 -2.1%	$166.48	$72.65 ▼ $200.00	$6.56B	-1.23	203,207 shs	184,763 shs
CRNX Crinetics Pharmaceuticals	$84.95	$84.64	$30.25 ▼ $85.01	$9.01B	0.08	2.43 million shs	N/A
LQDA Liquidia	$28.64 +2.3%	$71.62	$21.91 ▼ $93.61	$2.51B	0.61	3.29 million shs	8.39 million shs
TRLV Trulieve Cannabis	$10.71 -1.5%	$10.66	$4.62 ▼ $13.28	$2.09B	N/A	2.66 million shs	2.27 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	-2.10%	-4.64%	-0.68%	+8.82%	+117.09%
CRNX Crinetics Pharmaceuticals	0.00%	0.00%	0.00%	+101.16%	+104.16%
LQDA Liquidia	+2.32%	-58.15%	-58.90%	-63.71%	+29.89%
TRLV Trulieve Cannabis	-1.43%	-12.39%	-9.60%	+10.11%	+1,070,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$159.56 -2.1%	$166.48	$72.65 ▼ $200.00	$6.56B	-1.23	203,207 shs	184,763 shs
CRNX Crinetics Pharmaceuticals	$84.95	$84.64	$30.25 ▼ $85.01	$9.01B	0.08	2.43 million shs	N/A
LQDA Liquidia	$28.64 +2.3%	$71.62	$21.91 ▼ $93.61	$2.51B	0.61	3.29 million shs	8.39 million shs
TRLV Trulieve Cannabis	$10.71 -1.5%	$10.66	$4.62 ▼ $13.28	$2.09B	N/A	2.66 million shs	2.27 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	-2.10%	-4.64%	-0.68%	+8.82%	+117.09%
CRNX Crinetics Pharmaceuticals	0.00%	0.00%	0.00%	+101.16%	+104.16%
LQDA Liquidia	+2.32%	-58.15%	-58.90%	-63.71%	+29.89%
TRLV Trulieve Cannabis	-1.43%	-12.39%	-9.60%	+10.11%	+1,070,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	2.64	Moderate Buy	$218.73	37.08% Upside
CRNX Crinetics Pharmaceuticals	2.13	Hold	$83.44	-1.77% Downside
LQDA Liquidia	2.25	Hold	$83.69	192.22% Upside
TRLV Trulieve Cannabis	2.00	Hold	$15.00	40.06% Upside

Current Analyst Ratings Breakdown

Latest TRLV, CRNX, BLTE, and LQDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	LQDA Liquidia	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$58.00
10/2/2026	LQDA Liquidia	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$108.00 ➝ $30.00
10/2/2026	LQDA Liquidia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$130.00 ➝ $58.00
10/1/2026	LQDA Liquidia	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$106.00 ➝ $53.00
10/1/2026	LQDA Liquidia	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
10/1/2026	LQDA Liquidia	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
10/1/2026	LQDA Liquidia	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
10/1/2026	LQDA Liquidia	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$110.00 ➝ $72.00
9/22/2026	LQDA Liquidia	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C)
9/22/2026	LQDA Liquidia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
9/11/2026	TRLV Trulieve Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A
CRNX Crinetics Pharmaceuticals	$7.70M	1,170.54	N/A	N/A	$11.23 per share	7.56
LQDA Liquidia	$158.32M	16.19	N/A	N/A	$0.51 per share	56.16
TRLV Trulieve Cannabis	$1.14B	1.81	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$77.61M	-$2.73	N/A	175.34	N/A	N/A	-11.84%	-11.62%	11/9/2026 (Estimated)
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.04	N/A	N/A	N/A	-1,189.88%	-44.22%	-39.77%	11/5/2026 (Estimated)
LQDA Liquidia	-$68.92M	$1.37	20.91	6.54	N/A	30.74%	149.65%	36.30%	11/2/2026 (Estimated)
TRLV Trulieve Cannabis	N/A	N/A	N/A	18.79	N/A	N/A	N/A	N/A	N/A

Latest TRLV, CRNX, BLTE, and LQDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/7/2026	Q2 2026	TRLV Trulieve Cannabis	$0.06	$0.11	+$0.05	-$2.10	$268.82 million	$271.00 million
8/3/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	-$1.14	+$0.04	-$1.14	$14.84 million	$25.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A
TRLV Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	33.56	33.56
CRNX Crinetics Pharmaceuticals	N/A	15.57	15.53
LQDA Liquidia	0.63	2.31	2.12
TRLV Trulieve Cannabis	0.45	5.94	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
CRNX Crinetics Pharmaceuticals	98.51%
LQDA Liquidia	64.54%
TRLV Trulieve Cannabis	N/A

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
CRNX Crinetics Pharmaceuticals	3.80%
LQDA Liquidia	25.60%
TRLV Trulieve Cannabis	3.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	41	40.27 million	34.92 million	Not Optionable
CRNX Crinetics Pharmaceuticals	210	106.10 million	102.06 million	Optionable
LQDA Liquidia	216	89.51 million	66.60 million	Optionable
TRLV Trulieve Cannabis	5,000	192.57 million	185.27 million	N/A

TRLV, CRNX, BLTE, and LQDA Headlines

Recent News About These Companies

Best Cannabis Stocks To Add to Your Watchlist - October 2nd

October 2 at 12:01 PM | marketbeat.com

Cantor Fitzgerald Reaffirms Their Buy Rating on Trulieve Cannabis (TRLV)

October 1 at 10:20 PM | theglobeandmail.com

Cannabis Stocks To Consider - October 1st

October 1 at 1:01 PM | marketbeat.com

Best Cannabis Stocks To Follow Now - September 30th

September 30 at 1:01 PM | marketbeat.com

Cannabis Stocks To Watch Today - September 29th

September 29, 2026 | marketbeat.com

3 Cannabis Stocks to Watch Heading Out of September

September 29, 2026 | marijuanastocks.comM

Trulieve Secures Exclusive Alien Labs, Connected Licensing Rights in Florida, Texas

September 28, 2026 | marketscreener.comM

Promising Cannabis Stocks To Add to Your Watchlist - September 28th

September 28, 2026 | marketbeat.com

Trulieve Announces Exclusive Master Licensing Agreement with Connected for Florida and Texas

September 28, 2026 | prnewswire.com

Trulieve Cannabis Corp. (NYSE:TRLV) Sees Significant Increase in Short Interest

September 26, 2026 | americanbankingnews.com

Cannabis Stocks Enter A New Era For Investors nd Enthusiasts

September 25, 2026 | marijuanastocks.comM

Promising Cannabis Stocks To Follow Now - September 25th

September 25, 2026 | marketbeat.com

Trulieve Cannabis (NYSE:TRLV) Trading Up 7.7% - Should You Buy?

September 22, 2026 | marketbeat.com

Trulieve Cannabis Corp. Added to S&P Total Market and S&P Completion Indices

September 22, 2026 | prnewswire.com

Trulieve Cannabis (NYSE:TRLV) Trading Down 5% - Time to Sell?

September 18, 2026 | marketbeat.com

Trulieve Cannabis (TLN) Doubles Down on Florida as US Federal Legalization Stays Stuck

September 18, 2026 | news.alphastreet.comN

Curaleaf: Favorable Court Ruling Doesn't Repay Debt

September 14, 2026 | seekingalpha.com

Trulieve: As Regulatory Headwinds Wane, Value Creation Is On The Cards

September 11, 2026 | seekingalpha.com

Top Cannabis Stocks Worth Watching - September 11th

September 11, 2026 | marketbeat.com

Trulieve Cannabis Corp ouvre un dispensaire de cannabis médical à Dunwoody, en Géorgie

September 5, 2026 | zonebourse.comZ

Trulieve Expands Georgia Presence With New Dunwoody Medical Cannabis Dispensary

September 4, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLV, CRNX, BLTE, and LQDA Company Descriptions

Belite Bio NASDAQ:BLTE

$159.56 -3.42 (-2.10%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$159.46 -0.09 (-0.06%)

As of 10/2/2026 07:30 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.95 0.00 (0.00%)

As of 09/1/2026

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Liquidia NASDAQ:LQDA

$28.64 +0.65 (+2.32%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$28.58 -0.06 (-0.20%)

As of 10/2/2026 07:59 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Trulieve Cannabis NYSE:TRLV

$10.71 -0.16 (-1.47%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$10.73 +0.02 (+0.22%)

As of 10/2/2026 07:30 PM Eastern

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRLV, CRNX, BLTE, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRLV, CRNX, BLTE, and LQDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRLV, CRNX, BLTE, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLV, CRNX, BLTE, and LQDA Company Descriptions

Belite Bio NASDAQ:BLTE

Crinetics Pharmaceuticals NASDAQ:CRNX

Liquidia NASDAQ:LQDA

Trulieve Cannabis NYSE:TRLV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRLV, CRNX, BLTE, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRLV, CRNX, BLTE, and LQDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRLV, CRNX, BLTE, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLV, CRNX, BLTE, and LQDA Company Descriptions

Belite Bio NASDAQ:BLTE

Crinetics Pharmaceuticals NASDAQ:CRNX

Liquidia NASDAQ:LQDA

Trulieve Cannabis NYSE:TRLV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools